{"entity":{"id":"actym-therapeutics","kind":"company","name":"Actym Therapeutics","aka":[],"tldr":"Actym Therapeutics uses a weakened, engineered strain of Salmonella bacteria, given into a vein, to carry immune-activating signals into tumours. Its first medicine, ACTM-838, reached an early trial in advanced solid tumours, which the registry now lists as terminated.","summary":"Actym Therapeutics, Inc., of Berkeley, California, developed the STACT (S. Typhimurium-Attenuated Cancer Therapy) platform, an engineered, auxotrophic bacterial vehicle given systemically that accumulates in tumours and is taken up by tumour-resident phagocytic antigen-presenting cells, where it expresses therapeutic payloads. Its lead candidate ACTM-838 delivers an engineered IL-15 superagonist (IL-15plex) and a constitutively active engineered STING. The FDA cleared the IND in May 2024, and a phase 1a/1b dose-escalation study in advanced solid tumours in the United States and Australia (NCT06336148) followed; the ClinicalTrials.gov record shows the study as terminated. The company also lists an undisclosed oncology programme and a fibrosis programme, and its board includes partners from Brandon Capital, Panacea Venture, Illumina Ventures and the Boehringer Ingelheim Venture Fund. Its first registered cancer trial, NCT06336148, was posted on ClinicalTrials.gov in March 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.actymthera.com/"},{"label":"ClinicalTrials.gov: phase 1a/1b trial of ACTM-838 (NCT06336148)","url":"https://clinicaltrials.gov/study/NCT06336148"},{"label":"IND clearance for ACTM-838, 30 May 2024","url":"https://www.actymthera.com/news/actym-therapeutics-announces-ind-clearance-for-phase-1-clinical-trial-investigating-lead-program-actm-838-in-patients-with-solid-tumors"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["engineered-bacteria-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: actymthera.com home, about, pipeline, science and news pages and the 30 May 2024 IND clearance release. Founding year not stated on the company website.","The ClinicalTrials.gov record NCT06336148, read on 29 October 2026, gives the status as terminated; the reason was not read and no results were found. The company pipeline page still described ACTM-838 as in a phase 1a/b trial, so current status is uncertain.","Investors are not listed because the pages read name board members' firms, not a financing round. No STING or IL-15 target record exists in OnCo."],"hq":"Berkeley, CA","country":"US","companyType":"biotech","website":"https://www.actymthera.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/actym-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"engineered-bacteria-therapy","kind":"technology","name":"Engineered bacteria as living cancer drugs","route":"/technologies/engineered-bacteria-therapy/"}]}}